World Asset Management Inc lifted its position in shares of Mylan NV (NASDAQ:MYL) by 10.1% during the 1st quarter, HoldingsChannel reports. The fund owned 32,992 shares of the company’s stock after purchasing an additional 3,020 shares during the period. World Asset Management Inc’s holdings in Mylan were worth $935,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MYL. Norges Bank acquired a new stake in shares of Mylan during the 4th quarter valued at $169,463,000. Oregon Public Employees Retirement Fund boosted its holdings in shares of Mylan by 2,715.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,145,628 shares of the company’s stock valued at $224,000 after acquiring an additional 5,927,314 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in shares of Mylan by 69.1% during the 3rd quarter. Clearbridge Investments LLC now owns 4,280,371 shares of the company’s stock valued at $156,662,000 after acquiring an additional 1,749,631 shares in the last quarter. State of Tennessee Treasury Department boosted its holdings in shares of Mylan by 644.2% during the 4th quarter. State of Tennessee Treasury Department now owns 1,226,063 shares of the company’s stock valued at $33,595,000 after acquiring an additional 1,061,320 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Mylan by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock valued at $215,460,000 after acquiring an additional 1,026,731 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors.
Several equities research analysts recently weighed in on MYL shares. Zacks Investment Research downgraded Mylan from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 23rd. UBS Group downgraded Mylan from a “buy” rating to a “neutral” rating and cut their price objective for the company from $54.00 to $32.00 in a report on Wednesday, January 23rd. Morgan Stanley raised Mylan from an “equal weight” rating to an “overweight” rating and set a $35.00 price objective on the stock in a report on Wednesday, March 6th. They noted that the move was a valuation call. Sanford C. Bernstein downgraded Mylan from an “outperform” rating to a “market perform” rating and set a $33.00 price objective on the stock. in a report on Wednesday, February 27th. Finally, Mizuho reissued a “neutral” rating on shares of Mylan in a report on Thursday, January 31st. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $39.89.
Mylan (NASDAQ:MYL) last announced its earnings results on Tuesday, February 26th. The company reported $1.30 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.33 by ($0.03). The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.10 billion. Mylan had a return on equity of 19.06% and a net margin of 3.08%. The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.43 earnings per share. On average, equities research analysts forecast that Mylan NV will post 4.38 EPS for the current year.
In other Mylan news, insider Paul Campbell sold 11,533 shares of Mylan stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.81% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://weekherald.com/2019/05/03/mylan-nv-myl-stake-boosted-by-world-asset-management-inc.html.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Further Reading: Investing in Blue-Chip Stocks
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.